Title Page

Version: May 12, 2023

Title: HIV co-infection increases the risk of post-tuberculosis mortality among patients treated

for drug resistant tuberculosis

Running Title: HIV co-infection and post-TB mortality

Authors:

1. **Argita D. Salindri**, Department of Population Health Sciences, School of Public Health,
Georgia State University, Atlanta, GA, USA; and Division of Infectious Diseases and
Geographic Medicine, Department of Medicine, Stanford University School of Medicine,
Stanford, CA, USA

2. **Maia Kipiani**, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia;
David Tvildiani Medical University, Tbilisi, Georgia; and The University of Georgia,
Tbilisi, Georgia

3. **Nino Lomtadze**, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia;
David Tvildiani Medical University, Tbilisi, Georgia; and The University of Georgia,
Tbilisi, Georgia

4. **Nestani Tukvadze**, National Center for Tuberculosis and Lung Diseases, Tbilisi,
Georgia

5. **Zaza Avaliani**, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

6. **Henry M. Blumberg**, Division of Infectious Diseases, Department of Medicine, Emory
University School of Medicine Atlanta, GA, USA; Hubert Department of Global Health
and Department of Epidemiology, Rollins School of Public Health, Emory University,
Atlanta, GA, USA

7. **Katherine E. Masyn**, Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA

8. **Richard B. Rothenberg**, Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA

9. **Russell R. Kempker**, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

10. **Matthew J. Magee**, Hubert Department of Global Health and Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; and Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

Abstract: 248/250

Main Article Word Count: 3391/3000

Table/Figure Counts: 6/Not specified

References: 40/40

Summary (40/40 words):

Our findings provide evidence that TB patients with comorbidities, especially HIV, may have a significantly increased risk of post-TB mortality compared to those without comorbidities. We also found that most post-TB mortality occurred within three years after TB treatment completion.

Keywords: post-TB mortality; comorbidities; HIV co-infection; hyperglycemia; hepatitis C

Corresponding Author:

Argita Salindri, PhD, MPH

Division of Infectious Diseases and Geographic Medicine

Department of Medicine

Stanford University School of Medicine

Email: asalind@stanford.edu

Phone: +1 404 490 5906

Alternate Corresponding Author:

Matthew Magee, PhD, MPH

Hubert Department of Global Health

Emory University Rollins School of Public Health

Email: mjmagee@emory.edu

Phone: +1 404 727 9814

ABTSRACT

Background: We aimed to determine the relationship between common pre-existing

comorbidities in patients with tuberculosis (TB) (including human immunodeficiency virus [HIV],

diabetes, and hepatitis C virus [HCV]) with rates of all-cause mortality after TB treatment.

Methods: We conducted a retrospective cohort study among patients treated for rifampicin-

resistant and multi/extensively drug resistant (RR and M/XDR) TB in the country of Georgia

during 2009-2017. Eligible participants were >15 years of age with newly diagnosed, laboratory-

confirmed drug resistant TB who received second-line treatment. Exposures included HIV

serologic status, diabetes, and HCV status. The primary outcome was post-TB treatment

mortality determined by cross-validating vital status with Georgia's national death registry

through November 2019. We estimated hazard rate ratios (HR) and 95% confidence intervals

(CI) of post-TB mortality among participants with and without pre-existing comorbidities using

cause-specific hazard regressions.

Results: Among 1032 eligible patients included in our analyses, 34 (3.3%) participants died

during treatment and 87 (8.7%) died post-TB treatment. Among those who died post-TB

treatment, the median time to death was 21 months (IQR 7–39) after TB treatment ended. After

adjusting for potential confounders, the hazard rates of mortality post-TB treatment were higher

among participants with HIV co-infection (adjusted hazard ratio [aHR]=3.74, 95%CI 1.77–7.91)

compared to those without HIV co-infection.

Conclusions: In our cohort, post-TB mortality occurred most commonly in the first three years

after TB treatment ended. Additional post-TB care and follow-up, especially among patients with

TB and comorbidities (especially HIV co-infection), may reduce rates of mortality post-TB

treatment.

INTRODUCTION

Tuberculosis (TB) remains a leading cause of infectious disease death with an estimated mortality rate of nearly 1.6 million persons worldwide annually [1]. The END TB strategy aims to reduce TB mortality from 2015 to 2035 by 95% [2]. Importantly, the reported number of TB deaths is likely underestimated because TB-attributable mortality after treatment is not typically measured or reported [3]. More importantly, WHO reported that TB related mortality consistently increased for the first time after more than a decade since 2020, likely due to the COVID-19 pandemic [1]. To meet the END TB goals, it is essential to better understand TB-related mortality including those that occur after the completion of TB treatment.

Emerging epidemiologic evidence suggests that patients formerly treated for TB disease may have higher mortality rates compared to the general population [3, 4]. Despite microbial cure and favorable clinical outcomes, patients formerly treated for TB disease may have residual sequelae including pulmonary impairment or increased risk of non-communicable metabolic diseases [5-8]. However, to date, little is known regarding the relationship between pre-existing comorbidities (i.e., comorbidities diagnosed prior to or at the beginning of TB treatment) and post-TB mortality. To substantially reduce TB-related mortality, it is necessary to identify host risk factors, including pre-existing comorbidities, that are associated with post-TB mortality.

Previous studies have identified several demographic and behavioral characteristics associated with increased risks of post TB-mortality [4, 9-13]. For example, highly drug-resistant forms of TB such as multidrug-resistant TB (MDR TB) are associated with higher rates of mortality post-TB treatment [9, 14, 15]. However, the effect of common pre-existing comorbidities such as human immunodeficiency virus (HIV) co-infection, hyperglycemia (i.e., elevated blood glucose with or without diabetes), diabetes, or hepatitis C virus (HCV) co-infection remains unclear. Understanding the extent to which these pre-existing comorbidities

impact post-TB mortality rates will help identify prevention strategies to reduce post-TB mortality

rates.

Given existing knowledge gaps, we aimed to a) estimate the rate of all-cause mortality

post-TB treatment and b) determine the association between pre-existing comorbidities and

post-TB treatment mortality rates using data from patients treated with second line TB drugs

(SLDs) from the country of Georgia.

METHODS

Study Design and Setting

We conducted a retrospective cohort study among adults with (>15 years old) newly

diagnosed and laboratory-confirmed pulmonary TB. Patients treated with SLDs (including

rifampicin-resistant and multidrug/extensively drug resistant TB [RR and M/XDR TB]) reported

to the Georgian National Center for Tuberculosis and Lung Disease (NCTLD) surveillance

system from January 2009 – December 2017 were eligible. Drug-susceptible TB patients, drug

resistant TB patients with strains susceptible to rifampicin, and those with a history of prior TB

treatment were excluded from analyses. Briefly, per Georgian National TB guidelines, standard

of care performed at TB treatment initiation for those treated with SLDs includes complete blood

count, chest X-ray, sputum smear and culture, drug susceptibility testing (DST), fasting plasma

glucose (FPG), and rapid test of HIV infection. Additional tests to screen for other chronic

comorbidities like viral hepatitis (hepatitis C and B) infections were done since 2008.

Definitions and Study Measures

The primary exposures of this study were comorbidities diagnosed before or at TB

treatment initiation, including a) HIV co-infection, b) any hyperglycemia, and c) HCV co-

infection. HIV and HCV virus (HCV) co-infections were determined by antibody test performed

at the beginning of TB treatment and recorded in the surveillance system. Any hyperglycemia

was determined by either a self-reported previous diagnosis of type-2 diabetes (T2DM), or by

FPG. Patients with FPG ≥5.6 mmol/L or a self-reported prior T2DM diagnosis were categorized

as patients with "any hyperglycemia." Patients with FPG level <5.6mmol/L and no history of

diabetes diagnosis were classified as "non-hyperglycemic." We then separately defined

diabetes status using three different levels: 1) no diabetes (FPG < 5.6 mmol/L with no previous

diagnosis of T2DM), 2) pre-diabetes (FPG 5.6 – 6.9 mmol/L with no previous diagnosis of

T2DM), and 3) diabetes (FPG ≥7.0 mmol/L or previous diagnosis of T2DM). "Any primary

comorbidity" was defined if patients had a record of either HIV co-infection, any hyperglycemia,

or HCV co-infection. Other comorbidities recorded in the surveillance system (including self-

reported cardiovascular disease, kidney disease, ulcer, pancreatitis, chronic obstructive

pulmonary disease, silicosis, and sarcoidosis) were considered in the analyses by summing the

number of comorbidities and classified as "none", "1 – 2", and "≥3".

Our primary study outcome, all-cause mortality post-TB treatment, was determined by

cross-referencing patients' national unique identifier with mortality status recorded in the death

registry managed by the National Statistics Office of Georgia. Drug resistance was determined

according to phenotypic DST results and were classified as rifampicin-resistant (RR), multidrug

(MDR), pre-extensively (pre-XDR), and extensively drug-resistant (XDR) TB according to WHO

guidelines [16]. Other covariates included in our study (e.g., clinical TB treatment outcomes,

self-reported smoking status, anthropometric measures) were defined according to surveillance

records.

Statistical Analyses

Chi-square/Fisher's exact and Wilcoxon rank-sum tests were performed to assess

associations between patients' comorbidities status and post-TB mortality. Poisson regression

was used to estimate rates of all-cause mortality post-TB treatment (per 1,000 person-years

[PY]). We also built life tables to independently estimate the mortality rates per 6-month follow-

up period during and after TB treatment. These mortality rates were then plotted with *ggplot2*

package in R to observe mortality trend during and after TB treatment. Proportional hazard

models with competing risks were used to estimate the hazard rate ratios (HR) of all-cause

mortality post-TB treatment comparing patients with and without pre-existing comorbidities [17].

Survival time was calculated from TB treatment initiation to a) time of death as recorded in the

online TB surveillance system (for those who died during TB treatment), b) date of death

recorded in the national death registry (for those who died after TB treatment), or c) the end of

follow-up time for those who did not have the study events (i.e., alive by November 13, 2019,

when mortality queries were cross-referenced with the vital registry's office). In the cause-

specific models estimating the HR of mortality post-TB treatment, patients were censored if they

a) died during TB treatment (i.e., competing risk) or b) had no death indication on the date

mortality status was verified. Proportional hazard assumptions were assessed using 1)

Kolmogorov-type supremum and 2) Schoenfeld's residuals tests [18]. Covariates included in the

final multivariable models were selected considering established risk factors identified in

previous studies, observed bivariate associations, and directed acyclic graphs [19].

Stratified analyses were performed to determine whether the effect of pre-existing

comorbidities on all-cause mortality post-TB treatment varied among those who had favorable

(n=655) vs. poor TB treatment outcomes (i.e., including those who defaulted and were lost to

follow-up) (n=325). Additionally, we performed a subgroup analysis to assess the interactions

between pre-existing comorbidities and smoking status to determine if the association between

pre-existing comorbidities and all-cause mortality post-TB treatment varied by smoking status.

We assessed statistical interaction by including the cross-product terms (e.g., diabetes X

smoking, HIV X smoking) in multivariable models. Statistical analyses were performed using

SAS version 9.4 (Cary, North Carolina).

Sensitivity Analyses

Sensitivity analyses were performed to quantify systematic errors (i.e., bias) due to a)

distribution specification in the regression analyses, b) misclassification of any hyperglycemia

status and c) confounding effects from unmeasured confounders. We reported methods of and

bias-adjusted estimates from sensitivity analyses in Table S3.

RESULTS

Study Population and Characteristics

During the study period, there were 5,385 RR and M/XDR TB treatment episodes

recorded in the national TB surveillance system, 31.5% (1,697/5,385) of which were classified

as newly diagnosed RR and M/XDR cases (i.e., no prior history of TB treatment) (Figure 1). Of

these, 1,416 (83.4%) unique case met study eligibility criteria and were cross-referenced with

the country of Georgia's vital registry. We excluded 384 patients without unique national

identifier, leaving 1,032 patients (72.9%) included in our analyses (Figure 1). Patients excluded

due to missing vital status were similar to patients included in the analyses in regard to age,

gender, prevalence of MDR or pre-XDR TB, cavitary disease, hyperglycemia, and hepatitis C

and HIV co-infections. Among patients included, the majority were male (73%), and median age

was 35 years (interquartile range [IQR] 26 – 49) (Table 1). The prevalence of MDR TB was

44.7% (461/1,032) and pre-XDR TB was 29.1% (300/1,032). HIV co-infection was reported

among 3.8% (39/1,032, 95% confidence interval [CI] 2.7 – 5.1) and the prevalence of any

hyperglycemia was 22.7% (234/1,032, 95%CI 20.2 – 25.3), 115 (49.1% [115/234], 95%CI 42.8

– 55.5) of which were determined to have diabetes. HCV co-infection was reported among

14.7% (153/1,032, 95%CI 12.8 – 17.1) of study participants.

Among 1,032 patients included in the final analyses, 34 (3.3%) died during TB treatment

during 1502 PY follow-up (age-adjusted mortality rate during TB treatment=22.6 per 1,000 PY,

95%CI 17.9 – 27.4) with a median time to death of 4 months (IQR 1 – 7) after TB treatment

initiation. There were 87 (8.7%) post-TB deaths among 998 patients alive at the end of their TB

treatment during 4,857 PY of follow up (age-adjusted post-TB mortality rate=17.9 per 1,000 PY,

95%CI 11.9 – 23.9) (Table 2). Among those who died during TB treatment, the median age at

time of death was 48 years (IQR 34 – 52). Nearly half (38/87, 43.7% 95%CI 33.6 – 54.2) of

post-TB deaths were observed during the first year after TB treatment end, and the majority

(67/87, 77.0%) occurred within the first three years with a median time to death of 21 months

(IQR 7 – 39) after TB treatment was completed and/or stopped. Among those who died after-TB

treatment, the median age at time of death was 50 years (IQR 39 – 63).

Pre-Existing Comorbidities and All-Cause Mortality Post-Tuberculosis Treatment

Among 32 patients who had HIV co-infection, there were 9 deaths post-TB treatment

during 130 person-years (post-TB mortality rate 69.23, 95%CI 36.02 – 133.10). The median age

at time of post-TB death among those with HIV co-infection was 41 years (IQR 39 – 46). The

post-TB mortality rates among patients with TB who had pre-diabetes was 21.92 (95%CI 12.73

– 37.75) and 26.12 (95%CI 15.47 – 44.10) among those with diabetes. The median age at time

of post-TB death among those with pre-diabetes was 48 years (IQR 35 – 59) and 63 years (IQR

49 – 68) among those with diabetes. Among 147 patients with TB who had HCV co-infection,

there were 18 deaths post-TB treatment during 701 person-years (post-TB mortality rate 25.68,

95%CI 16.18 – 40.76). The median age at time of post-TB death among those with HCV co-

infection was 57 years (IQR 39 – 62). Among 641 patients with TB without HIV, hyperglycemia,

or HCV co-infection (i.e., no primary comorbidity), there were 41 deaths post-TB treatment

during 3128 person-years (post-TB mortality rate 13.11, 95%CI 9.65 – 17.80) with the median

age at time of post-TB death of 49 years (IQR 38 – 59).

Patients with HIV co-infection had significantly higher hazard rate of post-TB mortality

(adjusted hazard rate ratio [aHR]=3.74, 95%CI 1.77 – 7.91) compared to those without HIV co-

infection after adjusting for potential confounders (Table 3). In the same adjusted model, the

hazard rate of post-TB mortality among TB survivors with prediabetes was 1.48 (95%CI 0.78 –

2.78) and 1.06 (95%CI 0.53 – 2.12) among those with diabetes compared to those with

euglycemic. The hazard rate of all-cause post-TB mortality among TB survivors with HCV co-

infection was 1.21 (95%CI 0.68 – 2.59) times the hazard rate among those without HCV co-

infection. The adjusted hazard rate of all-cause post-TB mortality among TB survivors with any

primary comorbidity (i.e., HIV, prediabetes/diabetes, and HCV) was significantly higher

(aHR=2.03 (95%CI 1.33 – 3.10) compared to those without. Our estimates did not change

substantially in models with different covariates specification (Table S1).

Results From Subgroup, Interaction, and Sensitivity Analyses

Among patients with known smoking status (n=591), we found that the multiplicative

effects of HIV co-infection and smoking, hyperglycemia and smoking, or HCV and smoking on

mortality post-TB treatment were non-significant (statistical interaction p>0.05) (Table 4). We

found that post-TB mortality rates were highest at 6-month post TB treatment among those with

HIV co-infection, pre-diabetes/diabetes or HCV (Figure 2). Among those with HIV co-infection,

pre-diabetes/diabetes, or HCV co-infection, the median time from the end of TB treatment to

post-TB deaths were lowest among those aged 16 – 40 years (median=13 month, IQR 5 – 22)

and ≥65 years (median=14 month, IQR 14 – 25) compared to those among age 41 – 65 years

(median=27 month, IQR 6 – 39) (data not shown). Among those with known final TB treatment

end (n=980), the hazard rate ratios of mortality post-TB treatment were similar among patients

with HIV or pre-diabetes/diabetes regardless of their final TB treatment outcome (Table S2).

However, those with HCV co-infection who were successfully treated for TB were more likely to

die post-TB treatment compared to those with HCV co-infection but had poor final TB treatment

outcomes.

In the log-binomial models to estimate the cumulative risk of post-TB mortality, the

cumulative risk of post-TB mortality among those with HIV co-infection was 3.63 (95%CI 1.99 –

6.61) times the risk of those without HIV co-infection. The cumulative risk of post-TB mortality,

although non-significant, was modestly higher among those with hyperglycemia (cRR 1.59,

95%CI 1.00 – 2.52) and HCV co-infection (cRR 1.53, 95%CI 0.92 – 2.58) (Table S3).

The median of bias-adjusted RRs after accounting for any hyperglycemia

misclassification was 1.84 (2.5^{th} – 97.5^{th} percentile 1.10 – 2.92) in the non-differential model vs.

1.73 (2.5^{th} – 97.5^{th} percentile 1.21 – 2.37) in the differential models. This indicates that

misclassification of any hyperglycemia in our cohort may result in bias towards the null. The E-

values of ≥6.72, ≥2.56, and ≥2.45 could explain away the observed association for HIV co-

infection, hyperglycemia, HCV, and post-TB mortality risk.

DISCUSSION

In our large cohort of patients with rifampicin-resistant TB (n=1,032 with a median of

follow-up time of 5 years), nearly 1 among 11 died post-TB treatment. We reported a higher rate

of all-cause mortality rate in our cohort of patients treated for RR and M/XDR when compared to

mortality rates of Georgia's general population in 2019 (17.3 vs. 12.5/1,000 person-years) [20].

This increased rate of post-TB mortality is consistent with previously published studies in

different settings [3, 4, 10, 14, 21-23]. Furthermore, we found that post-TB mortality occurred

mostly in the first three years after TB treatment ended. Additionally, we observed a significantly

increased post-TB mortality risk among patients with HIV co-infection compared to those without

HIV co-infection. Understanding the effect of pre-existing comorbidities (especially HIV co-

infection) on post-TB mortality could help determine whether additional care post-TB treatment

completion is needed to reduce premature deaths associated with TB and comorbidities.

In our cohort, we reported nearly 4-fold increased hazard rates of all-cause mortality

post-TB treatment among RR and M/XDR patients with HIV co-infection compared to those

without. Similar to our findings, a prospective cohort study conducted in Vietnam reported that

the hazard rate of post-TB deaths among TB patients with HIV was 5.1 (95%CI 4.2 – 6.3) times

the hazard rate among TB patients without HIV [22]. However, this hazard estimation combined

patients who died before and after TB treatment. Another study using data from the HIV

Epidemiology in South American networks reported a higher hazard rate of death at five years

after TB treatment completion among HIV patients with TB diagnosis within 30 days of

enrollment to the HIV clinic vs. those without TB (aHR 1.57, 95%CI 1.25 – 1.99) [24]. In the

same study, the authors reported that among TB-HIV patients, a lower CD4 count was

associated with higher rates of deaths post-TB treatment (aHR 1.57, 95%CI 1.41 – 1.76). Unlike

this South America's study, which only included drug-sensitive TB (DSTB) patients, our study

only included patients with RR and M/XDR, and this may partially explain the higher effect of

HIV on post-TB mortality reported in our study. Furthermore, our study also had longer follow-up

time (up to eight years of follow-up time) and we utilized competing risks model to distinctly

modeled the hazard rates of deaths observed during and after TB treatment.

Hyperglycemia has been associated with increased risk of mortality during TB treatment

[25-27]. However, the association between hyperglycemia and the risk of post-TB mortality is

not well characterized. We reported a non-significantly higher crude rates as well as the relative

effect for post-TB treatment mortality among TB survivors with diabetes compared to those with

pre-diabetes or euglycemic. A retrospective cohort study using data from the vital statistics

conducted in Israel found that there were less deaths due to diabetes among patients

successfully treated for TB disease compared to the general population [4]. In contrast, a

prospective study conducted in Mexico reported a higher proportion of non-TB related deaths

post-TB treatment among patients with diabetes (4.9%) compared to those without diabetes

(2.5%) [28]. The inconsistent findings of the association between pre-existing diabetes and the

risk of post-TB deaths may be affected by the use of blood glucose-lowering agents and blood

glucose management during and post-TB treatment. For instance, metformin use was

associated with reduced mortality risk among patients in a study conducted in Taiwan [29].

Prospective clinical studies aiming to assess the impact of diabetes clinical characteristics

(including the use of blood glucose-lowering agents during TB treatment) on the risk of mortality

post-TB deaths are still warranted.

In our cohort, TB survivors with HCV co-infection had 25% higher rate of post-TB

mortality compared to those without HCV co-infection. To our knowledge, to date, there are

limited studies looking at the long-term outcomes of TB patients with HCV co-infection. It is well

known that anti-tuberculosis therapy, especially SLDs, may cause hepatotoxicity and could lead

to adverse TB treatment outcomes [30, 31]. Hepatotoxicity could also lead to permanent

damage to the liver and may increase the risk of deaths [32]. Alternatively, post-TB deaths we

were observing among patients with HCV co-infection in this cohort may be due to HCV-related

liver disease. However, since information on cause of death as well as time of HCV infection are

not known in this cohort, more epidemiologic evidence is needed to link HCV to mortality post-

TB treatment.

There are several plausible biological pathways to explain how pre-existing

comorbidities could increase the risk of post-TB mortality. First, patients with pre-existing

comorbidities may experience prolonged chronic and systematic inflammation during TB

treatment, which could lead to severe disease manifestations/complications (e.g., opportunistic

infections among patients with HIV co-infection, renal or heart disease among patients with

diabetes, and cirrhosis among patients with HCV co-infection) [33, 34] which, in turn, will

increase the risk of mortality post-TB treatment. Second, patients successfully treated for TB

with pre-existing comorbidities like T2DM may have carry over or residual complications such as

proatherogenic and abnormal lipid plasma profile, an established risk factor for cardiovascular

diseases [35]. Third, patients with pre-existing comorbidities may also have increased risks of

TB relapse (i.e., re-infection or recurrent after treatment) due to their impaired immune system

[36-38]. Further clinical studies are needed to establish which of these pathways is more

common among TB survivors with pre-existing comorbidities.

Our study subjects to several limitations. First, we performed our analyses among

patients treated from 2009 – 2017. Thus, cohort effects associated with changes in national TB

treatment guidelines and/or care for TB patients with pre-existing comorbidities are likely

affected our reported estimates. Second, we did not have data on the cause of death. Thus, we

were not able to assess whether mortalities post-TB treatment observed in this study are

directly associated with pre-existing comorbidities. Third, we did not have clinical information on

key measures for pre-existing comorbidities such as CD4 counts, viral load, blood glucose level

during TB treatment, or whether or not patients were on medications to manage their

comorbidities. Fourth, we identified several plausible sources of systematic errors, including

bias due to misclassification of hyperglycemia status. However, after running the sensitivity

analyses, we did not see any significant difference in our estimates that would change the

study's overall findings. Lastly, our cohort did not include non-TB individuals as a control group.

Thus, we were not able to draw direct comparison on mortality rates between TB patients vs.

non-TB individuals in Georgia.

In conclusion, we reported an overall high rate of post-TB deaths among patients treated

for RR and M/XDR, especially among those with pre-existing comorbidities. More importantly,

most post-TB deaths were observed within three years after TB treatment was

stopped/completed. Aggressive approaches to diagnose comorbidities and integrating TB and

non-communicable diseases care to reduce the risk of mortality after TB treatment are needed

to help prevent premature deaths. Additionally, continuous care for pre-existing comorbidities

(especially HIV co-infection) during and after TB treatment may reduce the increased risks of

deaths post-TB treatment.

ETHICS APPROVAL

This study was submitted to, reviewed, and approved by the Institutional Review Boards (IRBs) at Georgia State University, Emory University, Atlanta, USA and the ethics committee at National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (FWA00020831).

STUDY FUNDING

This work was supported in part by grants from the National Institutes of Health (NIH) including the National Institute of Allergy and Infectious Diseases (NIAID) [R03AI133172 to MJM, R03AI139871 to RRK, R01AI153152 to MJM] and the Fogarty International Center (FIC) [D43TW007124 to HMB for the "Emory-Georgia TB Research Training Program", R21TW011157 to MK and MJM]. ADS was supported by a Vanderbilt Emory Cornell Duke (VECD) Global Health Fellowship, funded by the NIH FIC NIH (D43TW009337). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICT OF INTEREST

We have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS

ADS, MJM, and RRK conceived the study design. ADS and MK obtained the data. ADS performed the analyses. ADS, MJM, HMB, RRK, MK provided interpretation of data for the work. ADS wrote the first draft of the manuscript. MJM, HMB, RRK revised the manuscript critically for important intellectual content. All authors reviewed and approved the final version of the manuscript.

ACKNOWLEDGEMENTS

We would like to thank Mamuka Chincharauli for his assistance in pooling data from the Georgia's TB online surveillance system.

REFERENCES

1.   World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization, **2022**.
2.   World Health Organization. The END TB strategy. Geneva: World Health Organization, **2015**.
3.   Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis **2019**.
4.   Shuldiner J, Leventhal A, Chemtob D, Mor Z. Mortality after anti-tuberculosis treatment completion: results of long-term follow-up. Int J Tuberc Lung Dis **2016**; 20(1): 43-8.
5.   Harries AD, Ade S, Burney P, Hoa NB, Schluger NW, Castro JL. Successfully treated but not fit for purpose: paying attention to chronic lung impairment after TB treatment. Int J Tuberc Lung Dis **2016**; 20(8): 1010-4.
6.   Pearson F, Huangfu P, McNally R, Pearce M, Unwin N, Critchley JA. Tuberculosis and diabetes: bidirectional association in a UK primary care data set. J Epidemiol Community Health **2019**; 73(2): 142-7.
7.   Salindri AD, Wang JY, Lin HH, Magee MJ. Post-tuberculosis incidence of diabetes, myocardial infarction, and stroke: Retrospective cohort analysis of patients formerly treated for tuberculosis in Taiwan, 2002 - 2013. Int J Infect Dis **2019**.
8.   Magee MJ, Salindri AD, Gujral UP, et al. Convergence of non-communicable diseases and tuberculosis: a two-way street? Int J Tuberc Lung Dis **2018**; 22(11): 1258-68.
9.   Blondal K, Rahu K, Altraja A, Viiklepp P, Rahu M. Overall and cause-specific mortality among patients with tuberculosis and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis **2013**; 17(7): 961-8.
10.   Christensen AS, Roed C, Andersen PH, Andersen AB, Obel N. Long-term mortality in patients with pulmonary and extrapulmonary tuberculosis: a Danish nationwide cohort study. Clin Epidemiol **2014**; 6: 405-21.
11.   Dangisso MH, Woldesemayat EM, Datiko DG, Lindtjorn B. Correction: Long-term outcome of smear-positive tuberculosis patients after initiation and completion of treatment: A ten-year retrospective cohort study. PLoS One **2018**; 13(4): e0196432.
12.   Wang XH, Ma AG, Han XX, et al. Survival and associated mortality risk factors among post-treatment pulmonary tubercolosis patients in the northwest of China. Eur Rev Med Pharmacol Sci **2015**; 19(11): 2016-25.
13.   Kolappan C, Subramani R, Kumaraswami V, Santha T, Narayanan PR. Excess mortality and risk factors for mortality among a cohort of TB patients from rural south India. Int J Tuberc Lung Dis **2008**; 12(1): 81-6.
14.   Miller TL, Wilson FA, Pang JW, et al. Mortality hazard and survival after tuberculosis treatment. Am J Public Health **2015**; 105(5): 930-7.
15.   Cox H, Kebede Y, Allamuratova S, et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med **2006**; 3(10): e384.
16.   World Health Organization. Definitions and Reporting Framework for Tuberculosis-2013 Revision. Geneva: World Health Organization, **2013**.
17.   Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation **2016**; 133(6): 601-9.
18.   Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning. Third Edition ed. New York: Springer, **2011**.

19.   Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology **1999**; 10(1): 37-48.
20.   National Statistics Office of Georgia. Deaths. Available at: https://www.geostat.ge/en/modules/categories/320/deaths. Accessed December 13.
21.   Basham CA, Karim ME, Cook VJ, Patrick DM, Johnston JC. Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985-2015: a time-dependent Cox regression analysis of linked immigration, public health, and vital statistics data. Can J Public Health **2020**.
22.   Fox GJ, Nguyen VN, Dinh NS, et al. Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam. Clin Infect Dis **2019**; 68(8): 1359-66.
23.   Tocque K, Convrey RP, Bellis MA, Beeching NJ, Davies PD. Elevated mortality following diagnosis with a treatable disease: tuberculosis. Int J Tuberc Lung Dis **2005**; 9(7): 797-802.
24.   Koenig SP, Kim A, Shepherd BE, et al. Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. Clin Infect Dis **2020**; 71(1): 215-7.
25.   Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med **2011**; 9: 81.
26.   Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health **2013**; 18(7): 822-9.
27.   Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. J Infect Dis **2016**; 213(7): 1163-72.
28.   Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax **2013**; 68(3): 214-20.
29.   Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis **2018**; 66(2): 198-205.
30.   Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med **1998**; 157(6 Pt 1): 1871-6.
31.   Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis **2015**; 21(6): 992-1001.
32.   Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. Med Sci Monit **2020**; 26: e920350.
33.   Kornfeld H, West K, Kane K, et al. High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India: A Report from the Effects of Diabetes on Tuberculosis Severity (EDOTS) Study. Chest **2016**; 149(6): 1501-8.
34.   Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep **2018**; 8(1): 4980.

35. Vrieling F, Ronacher K, Kleynhans L, et al. Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. EBioMedicine **2018**; 32: 192-200.
36. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet Infectious Diseases **2009**; 9(12): 737-46.
37. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis **2010**; 50 Suppl 3: S201-7.
38. Wu P-H, Lin Y-T, Hsieh K-P, Chuang H-Y, Sheu C-C. Hepatitis C Virus Infection Is Associated With an Increased Risk of Active Tuberculosis Disease: A Nationwide Population-Based Study. Medicine **2015**; 94(33): e1328-e.

Table 1 Demographic and clinical characteristics of patients treated with second-line tuberculosis drugs according to pre-existing comorbidity status, Georgia, 2009 – 2017 (N=1,032)

Characteristics	Total N=1032 N (%)	HIV positive[*] N (%) =39 (3.8) N (%)	Hyperglycemia[^] N (%) =234 (22.7) N (%)	HCV positive[#] N (%) =153 (14.7) N (%)
Demographic				
Age				
Years, median (IQR)	35 (26 – 49)	40 (35 - 47)	42.5 (32 – 54)	42 (34 – 50)
Age Group				
16 – 40	642 (62.2)	21 (53.9)	107 (45.7)	72 (47.1)
41 – 64	347 (33.6)	18 (46.2)	109 (46.6)	76 (49.7)
65+	43 (4.2)	0 (0)	18 (7.7)	5 (3.3)
Male Gender	753 (73.0)	33 (84.6)	189 (80.8)	148 (96.7)
Ethnicity, Georgian	942 (91.3)	33 (84.6)	212 (90.6)	142 (92.8)
Baseline Clinical Information				
BMI				
Kg/m^2, median (IQR)	20.8 (19.1 – 22.9)	21.2 (18.4 – 22.0)	21.6 (19.9 – 24.8)	21.1 (19.4 – 23.2)
BMI Category				
Underweight (BMI <18.5)	170 (18.6)	10 (27.0)	24 (11.4)	21 (15.6)
Normal (BMI 18.5 – 24.9)	648 (70.8)	23 (62.2)	135 (64.3)	95 (70.4)
Overweight (BMI 25.0 – 29.0)	76 (8.3)	4 (10.8)	38 (18.1)	17 (12.6)
Obese (BMI ≥30)	21 (2.3)	0 (0.0)	13 (6.2)	2 (1.5)
Missing	117	2	24	18
Smear Positive (n=983)	655 (66.6)	13 (36.1)	173 (75.9)	98 (68.1)
Culture Positive (n=883)	876 (99.2)	37 (100.0)	199 (99.0)	128 (99.2)
RR TB	195 (18.9)	4 (10.3)	42 (18.0)	28 (18.3)
MDR/pre-XDR TB	761 (73.7)	32 (82.1)	170 (72.7)	118 (77.1)
XDR TB	76 (7.4)	3 (7.7)	22 (9.4)	7 (4.6)
Abnormal Chest X-ray Findings (n=1014)	975 (96.2)	34 (89.5)	215 (93.1)	149 (98.7)
Cavitary Disease	285 (27.6)	5 (12.8)	64 (27.4)	44 (28.8)
Infiltrate	755 (73.2)	22 (56.4)	169 (72.2)	113 (73.9)
Disseminated TB disease	251 (24.3)	10 (25.6)	60 (25.6)	45 (29.4)
Other Risk Factors				

Characteristics	Total N=1032 N (%)	HIV positive[*] N (%) =39 (3.8) N (%)	Hyperglycemia[^] N (%) =234 (22.7) N (%)	HCV positive[#] N (%) =153 (14.7) N (%)
Contact with DRTB patients (n=591)	153 (14.8)	5 (25.0)	29 (21.2)	19 (17.9)
History of internally displaced (n=874)	36 (4.1)	2 (6.1)	5 (2.4)	6 (5.1)
Tobacco Use (n=591)	455 (44.1)	18 (90.0)	104 (75.9)	97 (91.5)
Excessive Alcohol Intake (n=998)	59 (5.9)	1 (2.7)	16 (7.1)	16 (11.0)
Other comorbidities				
Hepatitis B (n=735)	32 (3.1)	3 (13.6)	9 (5.1)	8 (5.7)
CVD	12 (1.2)	0 (0.0)	7 (5.6)	5 (4.9)
Renal disease	1 (0.4)	0 (0.0)	1 (0.4)	0 (0.0)
Ulcer	6 (2.3)	0 (0.0)	1 (0.4)	0 (0.0)
Pancreatitis	1 (0.4)	1 (2.6)	0 (0.0)	0 (0.0)
COPD	4 (1.5)	0 (0.0)	0 (0.)	1 (0.7)
Treatment Outcome (n=980)				
Completed/cured	655 (65.4)	10 (26.3)	157 (68.0)	73 (51.4)
Poor treatment outcome	325 (33.2)	26 (8.0)	74 (32.1)	69 (48.6)
Failed the treatment	44/325 (13.5)	5/26 (19.2)	13/74 (17.8)	10/69 (14.5)
Defaulted/LFU	247/325 (76.0)	14/26 (53.9)	58/74 (78.4)	53/69 (76.8)
Died during TB treatment	34/325 (10.5)	7/26 (26.9)	3/74 (4.1)	6/69 (8.7)
Return to care	95 (9.2)	6 (15.4)	32 (13.7)	18 (11.8)
Survival Status				
Alive	911 (88.3)	23 (59.0)	204 (87.2)	129 (84.3)
Mortality during treatment	34 (3.3)	7 (18.0)	3 (1.3)	6 (3.9)
Mortality post-TB treatment	87 (8.4)	9 (23.0)	27 (11.5)	18 (11.8)

*There were 96 patients with missing/unknown HIV co-infection status
^There were 220 with missing/unknown prediabetes/diabetes status
#There were 282 patients with missing/unknown HCV co-infection status

Abbreviations:
BMI – body mass index; CVD – cardiovascular diseases; DRTB – drug-resistant TB; LFU – lost to follow-up; HCV – hepatitis C virus; HIV – human immunodeficiency virus; IQR – interquartile range; MDR – multidrug resistant; RR – rifampicin resistant; TB – tuberculosis; XDR – extensively drug-resistant

Table 2 All-cause mortality post-tuberculosis among patients treated with second-line TB drugs with and without pre-existing comorbidities in Georgia, 2009 – 2017 (N=998)*

Characteristics	All-cause mortality post-tuberculosis treatment				Median time to death post-TB treatment, months (IQR)
	Death/Total (%)	Person time (Years)	Crude Rates (95%CI)	Rate Difference (95%CI)	
All cohort	**87/998 (8.7)**	**4857**	**17.91 (14.43 – 21.99)**		**21 (7 – 39)**
By comorbidity status					
HIV co-infection					
No	68/878 (7.7)	4195	16.12 (12.78 – 20.56)	Reference	22 (7 – 39)
Yes	9/32 (28.1)	130	69.23 (36.02 – 133.10)	**53.02 (7.63, 98.41)**	7 (4 – 9)
Missing	10/88 (11.4)	532	18.80 (10.11 – 34.94)	2.59 (-9.68, 14.86)	23 (13 – 46)
Hyperglycemia[†]					
No	41/558 (7.4)	2712	15.12 (11.13 – 20.53)	Reference	28 (9 – 43)
Yes	27/231 (11.7)	1129	23.91 (16.40 – 34.87)	8.80 (-1.34, 18.93)	19 (7 – 34)
Missing	19/209 (9.1)	1016	18.70 (11.93 – 29.32)	3.58 (-6.02, 13.18)	21 (6 – 40)
Diabetes Status					
No diabetes	41/558 (7.4)	2712	15.12 (11.13 – 20.53)	Reference	28 (9 – 43)
Pre-diabetes	13/119 (10.9)	593	21.92 (12.73 – 37.75)	6.80 (-5.98, 19.59)	17 (7 – 31)
Diabetes	14/112 (12.5)	536	26.12 (15.47 – 44.10)	11.00 (-3.44, 25.44)	22 (10 – 38)
Missing	19/209 (9.1)	1016	18.70 (11.93 – 29.32)	3.58 (-6.02, 13.18)	21 (6 – 40)
HCV co-infection					
No	46/580 (7.9)	2872	16.02 (12.00 – 21.38)	Reference	20 (9 – 39)
Yes	18/147 (12.2)	701	25.68 (16.18 – 40.76)	9.66 (-3.07, 2.24)	20 (8 – 38)
Missing	23/271 (8.5)	1284	17.91 (11.90 – 26.96)	1.90 (-6.77, 10.56)	22 (6 – 45)
Any Primary Comorbidity[‡]					
No	41/641 (6.4)	3128	13.11 (9.65 – 17.80)	Reference	28 (13 – 41)
Yes	46/357 (12.9)	1729	26.60 (19.93 – 35.52)	**13.50 (4.83 – 22.17)**	19 (6 – 38)
Number of Other Comorbidities[¶]					
0	60/699 (8.6)	3408	17.61 (13.67 – 22.67)	Reference	20 (7 – 39)
1 – 2	6/52 (11.5)	243	24.69 (11.09 – 54.96)	7.09 (-13.17, 27.34)	25 (15 – 28)
Missing	21/247 (8.5)	1206	17.41 (11.35 – 26.71)	-0.19 (-8.87, 8.49)	28 (7 – 45)

| Characteristics | All-cause mortality post-tuberculosis treatment | | | | Median time to death post-TB treatment, months (IQR) |
	Death/Total (%)	Person time (Years)	Crude Rates (95%CI)	Rate Difference (95%CI)	
By other important risk factors					
Smoking status					
Non-smoker	10/130 (7.7)	620	16.13 (8.68 – 29.98)	Reference	32 (15 – 43)
Smoker	37/437 (8.5)	2127	17.40 (12.60 – 24.01)	1.27 (-10.19, 12.73)	22 (10 – 39)
Missing/Unknown	40/431 (9.3)	2110	18.96 (13.91 – 25.84)	2.83 (-8.77, 14.42)	17 (6 – 39)
Baseline BMI					
Underweight (BMI <18.5)	16/158 (10.1)	730	21.92 (13.43 – 35.78)	5.75 (-5.87, 17.37)	20 (5 – 39)
Normal (BMI 18.5 – 24.9)	51/633 (8.1)	3155	16.14 (12.29 – 21.27)	Reference	21 (7 – 45)
Overweight/Obese (BMI ≥25.0)	12/94 (12.8)	439	27.33 (25.52 – 48.13)	11.17 (-4.92, 27.26)	29 (17 – 36)
Missing	8/113 (7.1)	533	15.01 (7.51 – 30.01)	-1.16 (-12.46, 10.15)	7 (4 – 28)

[*]34 patients who died during treatment were excluded from the post-TB mortality analyses

[†]Including patients with pre-diabetes and diabetes

[‡]Any primary comorbidity was defined as the presence of either HIV co-infection, hyperglycemia, or HCV co-infection

[¶]Other comorbidities included hepatitis B co-infection, cardiovascular disease, renal disease, ulcer, pancreatitis, and COPD (these were self-reported information and recorded in Georgia's TB surveillance system)

Abbreviations:

BMI – body mass index; CI – confidence interval; HCV – hepatitis C virus; HIV – human immunodeficiency virus; IQR – interquartile range; TB - tuberculosis

Table 3 Adjusted hazard rate ratios of tuberculosis mortality during and after treatment among patients treated with second-line TB drugs with and without pre-existing comorbidities in Georgia, 2009 – 2017 (N=1,032)

Comorbidities	Study Outcomes			
	Tuberculosis mortality during treatment (n=34)		Tuberculosis mortality after treatment (n=87)	
	cHR (95%CI)	aHR[*] (95%CI)	cHR (95%CI)	aHR[*] (95%CI)
HIV co-infection				
No	Reference	Reference	Reference	Reference
Yes	**9.33 (3.92 – 22.23)**	**11.52 (4.57 – 29.06)**	**4.56 (2.27 – 9.15)**	**3.74 (1.77 – 7.91)**
Missing	**4.10 (1.80 – 9.37)**	**3.70 (1.48 – 9.27)**	1.11 (0.57 – 2.17)	1.05 (0.53 – 2.12)
Hyperglycemia				
No	Reference		Reference	
Yes	0.37 (0.11 – 1.24)		1.60 (0.98 – 2.60)	
Missing	1.47 (0.70 – 3.06)		1.24 (0.72 – 2.14)	
Diabetes Status				
No diabetes	Reference	Reference	Reference	Reference
Pre-diabetes	NA	NA	1.47 (0.79 – 2.75)	1.48 (0.78 – 2.78)
Diabetes	0.76 (0.23 – 2.55)	0.75 (0.19 – 3.00)	1.73 (0.94 – 3.18)	1.06 (0.53 – 2.12)
Missing	1.47 (0.70 – 3.06)	1.72 (0.79 – 3.75)	1.24 (0.72 – 2.14)	1.45 (0.82 – 2.59)
HCV co-infection				
No	Reference	Reference	Reference	Reference
Yes	1.40 (0.55 – 3.56)	0.93 (0.33 – 2.66)	1.58 (0.92 – 2.73)	1.21 (0.68 – 2.15)
Missing	1.39 (0.65 – 2.96)	1.26 (0.55 – 2.87)	1.12 (0.68 – 1.85)	0.90 (0.53 – 1.55)
Any Primary Comorbidity[†]				
No	Reference		Reference	
Yes	1.42 (0.72 – 2.80)		**2.03 (1.33 – 3.10)**	
Number of Other Comorbidities[‡]				
0	Reference		Reference	
1 – 2	1.13 (0.26 – 4.71)		**1.40 (0.60 – 3.23)**	
Missing	0.95 (0.43 – 2.11)		0.99 (0.60 – 1.63)	
Smoking status				
Non-smoker	Reference	Reference	Reference	Reference
Smoker	0.91 (0.36 – 2.28)	0.85 (0.31 – 2.33)	1.07 (0.53 – 2.15)	1.00 (0.48 – 2.09)
Missing/Unknown	0.51 (0.19 – 1.41)	0.46 (0.16 – 1.31)	1.15 (0.58 – 2.31)	1.34 (0.66 – 2.74)
Baseline BMI				

Comorbidities	Study Outcomes			
	Tuberculosis mortality during treatment (n=34)		Tuberculosis mortality after treatment (n=87)	
	cHR (95%CI)	aHR[*] (95%CI)	cHR (95%CI)	aHR[*] (95%CI)
Underweight (BMI <18.5)	**3.15 (1.48 – 6.73)**	2.87 (0.31 – 2.33)	1.37 (0.78 – 2.41)	1.31 (0.72 – 2.38)
Normal (BMI 18.5 – 24.9)	Reference	Reference	Reference	Reference
Overweight/Obese (BMI ≥25.0)	1.35 (0.39 – 4.65)	1.34 (0.34 – 5.20)	1.72 (0.92 – 3.23)	1.20 (0.60 – 2.40)
Missing	1.49 (0.49 – 4.48)	1.36 (0.42 – 4.36)	0.93 (0.44 – 1.97)	0.88 (0.40 – 1.95)

[*]Model adjusted for HIV-coinfection, diabetes status, HCV co-infection, age, gender, cavitary disease, type of drug resistance, smoking, and BMI at TB treatment initiation (fully-adjusted model)
[†]Any comorbidity was defined as the presence of either hyperglycemia, hepatitis C, or HIV co-infection
[‡]Other comorbidities such as cardiovascular disease, renal disease, ulcer, pancreatitis, COPD, silicosis, sarcoidosis were included

Abbreviations:
aHR – adjusted hazard rate ratios; BMI – body mass index; cHR – crude hazard rate ratios; CI – confidence interval; HCV – hepatitis C virus; HIV – human immunodeficiency virus

Bold indicates that the finding is statistically significant at α=0.05

Table 4 Subgroup analyses to assess statistical interaction between pre-existing comorbidities and smoking on mortality post-tuberculosis among adult tuberculosis patients previously treated with second-line tuberculosis drugs in Georgia, 2009 – 2017 (N=591)

Smoking Status	Comorbidities Status	Post-TB mortality (%)	cHR (95%CI)	Adjusted Model	
				aHR* (95%CI)	p-values for the interaction term
HIV Co-infection					
Non-smokers	HIV Negative	9/117 (7.7)	Reference	Reference	
	HIV Positive	1/2 (50.0)	**13.68 (1.63 – 114.64)**	**12.72 (1.41 – 114.87)**	0.8903
Smokers	HIV Negative	32/399 (8.0)	Reference	Reference	
	HIV Positive	4/18 (22.2)	**4.72 (1.65 – 13.49)**	**4.87 (1.70 – 13.94)**	
Hyperglycemia (i.e., pre-diabetes and diabetes combined)					
Non-smokers	No hyperglycemia	7/74 (9.5)	Reference	Reference	
	Hyperglycemia	2/33 (6.1)	0.66 (0.14 – 3.17)	0.35 (0.07 – 1.76)	0.5909
Smokers	No hyperglycemia	19/256 (7.4)	Reference	Reference	
	Hyperglycemia	8/104 (7.7)	1.00 (0.44 – 2.29)	0.81 (0.35 – 1.88)	
Diabetes					
Non-smokers	No diabetes	7/74 (9.5)	Reference	Reference	
	Pre-diabetes	2/17 (11.8)	1.29 (0.27 – 6.21)	0.85 (0.15 – 4.86)	
	Diabetes	0/16 (0.0)	NA	NA	0.3569
Smokers	No diabetes	19/256 (7.4)	Reference	Reference	
	Pre-diabetes	4/51 (7.8)	1.02 (0.35 – 3.01)	1.08 (0.36 – 3.20)	
	Diabetes	4/53 (7.6)	0.98 (0.33 – 2.88)	0.64 (0.21 – 1.94)	
Hepatitis C					
Non-smokers	HCV Negative	4/84 (4.8)	Reference	Reference	
	HCV Positive	1/9 (11.1)	2.55 (0.28 – 22.86)	3.43 (0.35 – 33.69)	
Smokers	HCV Negative	15/232 (6.5)	Reference	Reference	0.8911
	HCV Positive	11/97 (11.3)	1.96 (0.90 – 4.26)	1.72 (0.79 – 3.75)	

Abbreviations: aHR – adjusted hazard rate ratios; cHR – crude hazard rate ratios; CI – confidence interval; HCV – hepatitis C virus; HIV – human immunodeficiency virus; TB – tuberculosis

*Model adjusted for age and gender
[†]Wald chi-square p-value for the interaction term between pre-diabetes and smoking
[‡]Wald chi-square p-value for the interaction term between diabetes and smoking
Bold indicates that the finding is statistically significant at α=0.05

FIGURES LEGENDS

Flowchart of patient selection according to inclusion criteria (i.e., non-pediatric TB cases with no prior history of TB treatment). Patients were excluded if they had no pulmonary involvement, culture confirmation at the beginning of TB treatment, or unknown vital status during and after TB treatment.

These plots depict the trend of mortality rates (expressed per 1,000 population) reported during and after TB treatment among all cohort, those without HIV, diabetes or hepatitis C (i.e., no comorbidity), and those with HIV, pre-diabetes/diabetes, hepatitis C.

FIGURES

Figure 1 Study flow

Figure 2 Trend of mortality rates reported during and after TB treatment stratified by comorbidity status (N=1,032)